Adaptive Biotechnologies raised its 2026 outlook on the back of accelerating adoption of its ClonoSeq minimal residual disease (MRD) assay, guiding MRD revenue to $255–$265 million and projecting 30% test‑volume growth. CEO Chad Robins told analysts the company expects broader clinical adoption, EMR integration and regulatory/clinical endorsement of MRD as drivers of both clinical and trial services demand. Adaptive also plans to raise average selling prices through payor renegotiations. The company flagged MRD as a strategic growth engine spanning multiple hematologic malignancies and registrational trials, signaling continued commercialization momentum for blood‑based cancer monitoring.